Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Assets Average: 2015-2025

Historic Assets Average for Zevra Therapeutics (ZVRA) over the last 10 years, with Sep 2025 value amounting to $263.2 million.

  • Zevra Therapeutics' Assets Average rose 56.68% to $263.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $263.2 million, marking a year-over-year increase of 56.68%. This contributed to the annual value of $175.2 million for FY2024, which is 21.83% up from last year.
  • Zevra Therapeutics' Assets Average amounted to $263.2 million in Q3 2025, which was up 22.71% from $214.5 million recorded in Q2 2025.
  • Zevra Therapeutics' Assets Average's 5-year high stood at $263.2 million during Q3 2025, with a 5-year trough of $50.8 million in Q1 2021.
  • For the 3-year period, Zevra Therapeutics' Assets Average averaged around $164.6 million, with its median value being $161.8 million (2024).
  • Per our database at Business Quant, Zevra Therapeutics' Assets Average skyrocketed by 1,105.22% in 2021 and then fell by 15.14% in 2023.
  • Zevra Therapeutics' Assets Average (Quarterly) stood at $135.1 million in 2021, then dropped by 13.04% to $117.4 million in 2022, then spiked by 32.53% to $155.7 million in 2023, then climbed by 18.75% to $184.8 million in 2024, then skyrocketed by 56.68% to $263.2 million in 2025.
  • Its Assets Average was $263.2 million in Q3 2025, compared to $214.5 million in Q2 2025 and $175.4 million in Q1 2025.